Stem cells-derived suicide gene exosomes: a promising platform for innovative cancer therapy

Area of Science:

• Oncology
• Biotechnology
• Nanomedicine

Background:

• Metastatic tumors often lack effective treatment options.
• Small extracellular vesicles, particularly exosomes, are emerging as novel drug delivery vehicles.
• Current cancer therapies require innovative approaches for improved efficacy.

Purpose of the Study:

• To review recent advancements in suicide gene exosome therapy for cancer.
• To explore the potential of engineered exosomes as intracellular anti-cancer drugs.
• To highlight therapeutic outcomes and future directions for exosome-based cancer treatments.

Main Methods:

• Production of suicide gene exosomes from genetically modified human mesenchymal stem cells (MSCs) expressing yeast cytosine deaminase::uracil phosphoribosyl transferase (yCD::UPRT).
• Utilizing tumor-targeting exosomes to convert the prodrug 5-fluorocytosine (5-FC) into the cytotoxic compound 5-fluorouracil (5-FU) within the tumor microenvironment.
• Investigating suicide gene exosomes derived from Herpes Simplex Virus thymidine kinase and ganciclovir.

Main Results:

• Engineered exosomes effectively convert prodrugs into cytotoxic agents specifically within tumor cells.
• Combined therapy using suicide gene exosomes from MSCs and cancer-associated fibroblasts (CAFs) shows promise for aggressive tumors.
• In vitro and in vivo studies demonstrate therapeutic potential of suicide gene exosomes.

Conclusions:

• Suicide gene exosomes represent a promising platform for intracellular anti-cancer drug delivery.
• Exosome-based therapies can be enhanced with additional drugs and customized for targeted delivery.
• Further research into therapeutically beneficial exosomes holds significant potential for future cancer treatment strategies.